December 4, 2016 09:34 AM EST

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

Arsalan Arif

Founder

Two weeks ago, Novartis stepped in with a deal to buy Selexys Pharmaceuticals and its Phase III-ready sickle cell disease drug crizanlizumab, an anti …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

Arsalan Arif

Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

What makes a PhII drug worth up to $665M? Re­searchers spell it out for No­var­tis

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway